The chronic obstructive pulmonary disBuyease market size reached a value of USD 13,862.5 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 20,107.2 Million by 2035, exhibiting a growth rate (CAGR) of 3.49% during 2025-2035.

The chronic obstructive pulmonary disease (COPD) market is expected to grow significantly by the year 2025. This is due to advances in awareness, diagnostics, and treatment options. As a condition that includes chronic bronchitis and emphysema, COPD is a long-term obstructive pulmonary condition which makes breathing difficult and decreases an individual’s quality of life. Currently, there is a need for appropriate management of COPD due to the increase in air pollution around the world, coupled with an older population.

The increasing utilization of combination inhalers is one of the major trends in the COPD market. Combination inhalers allow for the simultaneous delivery of bronchodilators and corticosteroids, assisting with breathing and decreasing inflammation. As of 2025, pharmaceutical companies are concentrating on enhancing the ergonomic features of the inhalers to ensure easier usage, especially among older patients. Another key trend is the emergence of mobile health applications and smart inhalers designed to monitor the use of medication, lung function, and other respiratory symptoms. These advanced tools are especially helpful to physicians in customizing CPRT to ward off severe attacks. The use of artificial intelligence in patient monitoring is also aiding in predicting serious complications before they arise.

The concentration on early detection is also impacting the COPD industry. In high-risk groups, such as smokers or those exposed to industrial pollutants, more patients are undergoing lung function tests as part of routine health assessments. This provides a more effective intervention and is cost effective for the healthcare system, resulting in improved outcomes. Moreover, the expansion of the market is being fueled by the continuing development of new drugs. Biologic therapies that work only on specific molecules of the body to amend illnesses, which are advanced and have limited response to standard treatment, are gaining traction for severe cases of COPD. These therapies promise lower side effects and better relief for the patient, allowing companies to mark more investment into longer lasting and low side effect treatment-teb.

Request for a sample of this report: https://www.imarcgroup.com/chronic-obstructive-pulmonary-disease-market/requestsample

Countries Covered:

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Analysis Covered Across Each Country:

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the chronic obstructive pulmonary disease market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the chronic obstructive pulmonary disease market

Reimbursement scenario in the market

In-market and pipeline drugs

This report also provides a detailed analysis of the current chronic obstructive pulmonary disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs:

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

Drug overview

Mechanism of action

Regulatory status

Clinical trial results

Drug uptake and market performance

Competitive Landscape with key players:

The competitive landscape of the chronic obstructive pulmonary disease market has been studied in the report with the detailed profiles of the key players operating in the market.

1. Viatris Inc.

2. AstraZeneca

3. Boehringer Ingelheim

4. AstraZeneca

Buy the Full Report with TOC: https://www.imarcgroup.com/checkout?id=7288&method=809

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145